|
Study
|
ALK+ (N)/Total(N)
|
Efficacy
|
|
Studies with no control or adjustment for confounding factors
|
|
Paik et al. [19]
|
28 ALK+/735
stage I-III
|
Median DFS:
• 76.4 months in ALK+
• 71.3 months in ALK- ( p =0.66 vs.ALK+)
|
|
Fukui et al. [20]
|
28 ALK+/720
adeno cases
all stages
|
5-year DFS rate:
• 74% in ALK+
• 68% in ALK- (p = 0.45 vs.ALK+)
|
|
Zhou et al. [27]
|
12 ALK+/134
stage IA
|
5-year DFS rate:
• 100% in ALK+
• 29.5% in ALK- (p = 0.04 vs.ALK+)
|
|
|
9 ALK+/165
stage IIIA
|
Median DFS:
• 6 months in ALK+
• 16 months in ALK- ( p =0.0057 vs.ALK+)
|
|
Studies with control or adjustment for confounding factors
|
|
Kim et al. [5]
|
11 ALK+/119
never-smokers,
all stagesa
|
Median RFS:
• 20.0 months in ALK+
• 39.7 months in EGFR mu
• 21.4 months in KRAS mu
• 26.8 months in WT/WT/WT
|